Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in new onset metastatic castration-resistant prostate cancer (mCRPC).

Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N.

Mol Cancer Ther. 2018 Dec 26. pii: molcanther.0739.2018. doi: 10.1158/1535-7163.MCT-18-0739. [Epub ahead of print]

PMID:
30587554
2.

Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making.

Martin C, Haaland B, Tward AE, Dechet C, Lowrance W, Stephenson RA, Hanson H, O'Neil B.

J Urol. 2018 Oct 23. pii: S0022-5347(18)44023-2. doi: 10.1016/j.juro.2018.10.014. [Epub ahead of print]

PMID:
30366023
3.

Developmentally regulated H2Av buffering via dynamic sequestration to lipid droplets in Drosophila embryos.

Johnson MR, Stephenson RA, Ghaemmaghami S, Welte MA.

Elife. 2018 Jul 25;7. pii: e36021. doi: 10.7554/eLife.36021.

4.

Quality of Life Following Prostatectomy as a Function of Surgery Type and Degree of Nerve Sparing.

Strassberg DS, Zavodni SM, Gardner P, Dechet C, Stephenson RA, Sewell KK.

Curr Urol. 2017 Nov;11(1):16-20. doi: 10.1159/000447189. Epub 2017 Nov 30.

5.

Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death.

Albright FS, Stephenson RA, Agarwal N, Cannon-Albright LA.

Prostate. 2017 Jan;77(1):41-48. doi: 10.1002/pros.23247. Epub 2016 Aug 16.

PMID:
27527734
6.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ; ABCTB Investigators, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A; AOCS Study Group & Australian Cancer Study (Ovarian Cancer); APCB BioResource, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT; kConFab Investigators, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC, Jones M, Lush M, Hildebrandt MA, Hou MF, Schoemaker MJ, Garcia-Closas M, Bogdanova N, Rahman N; NBCS Investigators, Le ND, Orr N, Wentzensen N, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P, Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist R, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SE, Gapstur SM, Kjær SK, Pejovic T, Tammela TL; GENICA Network; PRACTICAL consortium, Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, Menon U, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu XO, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D.

Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.

7.

Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21.

Teerlink CC, Leongamornlert D, Dadaev T, Thomas A, Farnham J, Stephenson RA, Riska S, McDonnell SK, Schaid DJ, Catalona WJ, Zheng SL, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Giles GG, Southey MC, Fitzgerald LM, Rinckleb A, Luedeke M, Maier C, Stanford JL, Ostrander EA, Kaikkonen EM, Sipeky C, Tammela T, Schleutker J, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Xu J, Cancel-Tassin G, Cussenot O, Mandal D, Laurie C, Laurie C; PRACTICAL consortium; International Consortium for Prostate Cancer Genetics, Thibodeau SN, Eeles RA, Kote-Jarai Z, Cannon-Albright L.

Hum Genet. 2016 Aug;135(8):923-38. doi: 10.1007/s00439-016-1690-6. Epub 2016 Jun 4.

8.

Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer.

Agarwal N, Alex AB, Farnham JM, Patel S, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L.

J Urol. 2016 Oct;196(4):1112-6. doi: 10.1016/j.juro.2016.04.079. Epub 2016 May 3.

PMID:
27150425
9.

The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.

O'Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF.

J Urol. 2016 Feb;195(2):321-9. doi: 10.1016/j.juro.2015.08.092. Epub 2015 Sep 3.

10.

Sedimentary geology of the middle Carboniferous of the Donbas region (Dniepr-Donets Basin, Ukraine).

van Hinsbergen DJ, Abels HA, Bosch W, Boekhout F, Kitchka A, Hamers M, van der Meer DG, Geluk M, Stephenson RA.

Sci Rep. 2015 Mar 20;5:9099. doi: 10.1038/srep09099.

11.

Prostate cancer risk prediction based on complete prostate cancer family history.

Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, Albright LA.

Prostate. 2015 Mar 1;75(4):390-8. doi: 10.1002/pros.22925. Epub 2014 Nov 18.

12.

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju268. doi: 10.1093/jnci/dju268. Print 2014 Nov. Erratum in: J Natl Cancer Inst. 2014 Nov;106(11):dju372 doi:10.1093/jnci/dju372.

13.

Use of a polytetrafluoroethylene (GORE-TEX) bolster to close the renal parenchymal defect during open partial nephrectomy.

Redshaw JD, West JM, Stephenson RA, Lowrance WT, Hamilton BD, Southwick AW, Dechet CB.

Urology. 2014 Sep;84(3):707-11. doi: 10.1016/j.urology.2014.06.004.

PMID:
25168556
14.

Identification of specific Y chromosomes associated with increased prostate cancer risk.

Cannon-Albright LA, Farnham JM, Bailey M, Albright FS, Teerlink CC, Agarwal N, Stephenson RA, Thomas A.

Prostate. 2014 Jun;74(9):991-8. doi: 10.1002/pros.22821. Epub 2014 May 6.

15.

Climacturia after definitive treatment of prostate cancer.

O'Neil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO.

J Urol. 2014 Jan;191(1):159-63. doi: 10.1016/j.juro.2013.06.122. Epub 2013 Sep 16.

PMID:
24050893
16.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF.

Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi: 10.1038/ng.2560.

17.

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; Australian Prostate Cancer Bioresource; PRACTICAL Consortium, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA.

Hum Mol Genet. 2013 Jan 15;22(2):408-15. doi: 10.1093/hmg/dds425. Epub 2012 Oct 12.

18.

Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States.

Lowrance WT, Eastham JA, Savage C, Maschino AC, Laudone VP, Dechet CB, Stephenson RA, Scardino PT, Sandhu JS.

J Urol. 2012 Jun;187(6):2087-92. doi: 10.1016/j.juro.2012.01.061. Epub 2012 Apr 11.

19.

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.

Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB, Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F, Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dörk T, Andriole G, Dickinson JL, Cybulski C, Lubinski J, Spurdle A, Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY, Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ, Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ, Tymrakiewicz M, Mahmud N, Guy M, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English DR, Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Røder MA, Tybjærg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R, Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L, Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B, Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD, Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource; PRACTICAL Consortium.

Nat Genet. 2011 Jul 10;43(8):785-91. doi: 10.1038/ng.882.

20.

Spangolite: an s = 1/2 maple leaf lattice antiferromagnet?

Fennell T, Piatek JO, Stephenson RA, Nilsen GJ, Rønnow HM.

J Phys Condens Matter. 2011 Apr 27;23(16):164201. doi: 10.1088/0953-8984/23/16/164201. Epub 2011 Apr 6.

PMID:
21471624
21.

Synthesis and structure of pillared molybdates and tungstates with framework layers.

Nicholls JL, Hulse SE, Callear SK, Tizzard GJ, Stephenson RA, Hursthouse MB, Clegg W, Harrington RW, Fogg AM.

Inorg Chem. 2010 Sep 20;49(18):8545-51. doi: 10.1021/ic101145p.

PMID:
20718486
22.

A detailed investigation of the aza-Prins reaction.

Dobbs AP, Guesné SJ, Parker RJ, Skidmore J, Stephenson RA, Hursthouse MB.

Org Biomol Chem. 2010 Mar 7;8(5):1064-80. doi: 10.1039/b915797b. Epub 2010 Jan 5.

PMID:
20165797
23.

Patterns of enlarged lymph nodes in patients with metastatic renal cell carcinoma.

Hadley DA, Stephenson RA, Samlowski WE, Dechet CB.

Urol Oncol. 2011 Nov-Dec;29(6):751-5. doi: 10.1016/j.urolonc.2009.10.013. Epub 2010 Jan 6.

PMID:
20056460
24.

U.S. Food and Drug Administration and off-label use of expandable metal biliary stents within the peripheral vasculature.

Yustein AS, Schultz D, Neuland C, Buckles DS, Nipper JC, Stephenson RA, Gonzalez G.

J Vasc Interv Radiol. 2008 Jul;19(7):965-9. Review.

PMID:
18672491
25.

5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study.

Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL.

J Urol. 2008 May;179(5 Suppl):S40-4. doi: 10.1016/j.juro.2008.03.136.

PMID:
18405749
26.

Risk stratification for positive lymph nodes in prostate cancer.

Pettus JA, Masterson TA, Abel EJ, Middleton RG, Stephenson RA.

J Endourol. 2008 May;22(5):1021-5. doi: 10.1089/end.2007.0129.

PMID:
18393648
27.

Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study.

Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, Hoffman RM, Potosky AL.

J Urol. 2005 Aug;174(2):646-50; discussion 650.

PMID:
16006930
29.

5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study.

Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL.

J Urol. 2005 May;173(5):1701-5.

PMID:
15821561
30.

Multiple abnormalities detected by dye reversal genomic microarrays in prostate cancer: a much greater sensitivity than conventional cytogenetics.

Pettus JA, Cowley BC, Maxwell T, Milash B, Stephenson RA, Rohr LR, Hoff C, Brothman AR.

Cancer Genet Cytogenet. 2004 Oct 15;154(2):110-8.

PMID:
15474145
31.

Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.

Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC.

J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67.

PMID:
15367568
32.

Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location.

Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA.

J Urol. 2004 Jul;172(1):129-32.

PMID:
15201752
33.

Renal cell carcinoma in horseshoe kidney with vena caval involvement.

Pettus JA, Jameson JJ, Stephenson RA.

J Urol. 2004 Jan;171(1):339. Review. No abstract available.

PMID:
14665915
34.

Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Hoffman RM, Harlan LC, Klabunde CN, Gilliland FD, Stephenson RA, Hunt WC, Potosky AL.

J Gen Intern Med. 2003 Oct;18(10):845-53.

35.
36.

General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study.

Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL.

J Clin Oncol. 2003 Mar 15;21(6):1147-54.

PMID:
12637483
38.

Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.

Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL.

J Natl Cancer Inst. 2002 Mar 20;94(6):430-7.

PMID:
11904315
39.

Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.

Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA.

J Natl Cancer Inst. 2001 Dec 19;93(24):1864-71.

PMID:
11752011
40.

Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.

Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM.

J Clin Oncol. 2001 Sep 1;19(17):3750-7.

PMID:
11533098
41.

Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study.

Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Hoffman RM, Eley JW, Harlan LC, Potosky AL.

J Clin Oncol. 2001 May 1;19(9):2517-26.

PMID:
11331331
42.

Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.

Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL.

J Natl Cancer Inst. 2001 Mar 7;93(5):388-95.

PMID:
11238701
43.

A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1.

Dai Q, Deubler DA, Maxwell TM, Zhu XL, Cui J, Rohr LR, Stephenson RA, Brothman AR.

Genomics. 2001 Feb 1;71(3):324-9.

PMID:
11170749
44.

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC.

J Natl Cancer Inst. 2000 Oct 4;92(19):1582-92.

PMID:
11018094
45.

The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis.

Albertsen PC, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, Stanford JL, Stephenson RA.

J Urol. 2000 Apr;163(4):1138-43.

PMID:
10737483
46.

Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins.

Bansal A, Murray DK, Wu JT, Stephenson RA, Middleton RG, Meikle AW.

J Clin Endocrinol Metab. 2000 Mar;85(3):1272-6.

PMID:
10720075
47.

Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.

Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL.

JAMA. 2000 Jan 19;283(3):354-60.

PMID:
10647798
48.
49.

Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.

Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS.

J Natl Cancer Inst. 1999 Oct 20;91(20):1719-24. No abstract available.

PMID:
10528021
50.

Role of transurethral resection of the prostate in population-based prostate cancer incidence rates.

Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA.

Am J Epidemiol. 1999 Oct 15;150(8):848-60.

PMID:
10522656

Supplemental Content

Loading ...
Support Center